MX388587B - Procedimiento para la preparacion de 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona. - Google Patents
Procedimiento para la preparacion de 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona.Info
- Publication number
- MX388587B MX388587B MX2019000207A MX2019000207A MX388587B MX 388587 B MX388587 B MX 388587B MX 2019000207 A MX2019000207 A MX 2019000207A MX 2019000207 A MX2019000207 A MX 2019000207A MX 388587 B MX388587 B MX 388587B
- Authority
- MX
- Mexico
- Prior art keywords
- cyclopent
- enyl
- pyrimidin
- dihydroxy
- hydroxymethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
Se describen procedimientos para la preparación de 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1H-pirimidin-2-ona (13, RX-3117) y sus intermediarios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800475P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030635 WO2014145807A1 (en) | 2013-03-15 | 2014-03-17 | Process for the preparation of 4-amino-1-((1s,4r, 5s)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1h-pyrimidin-2-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX388587B true MX388587B (es) | 2025-03-20 |
Family
ID=50639998
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000207A MX388587B (es) | 2013-03-15 | 2014-03-17 | Procedimiento para la preparacion de 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona. |
| MX2019006783A MX385963B (es) | 2013-03-15 | 2014-03-17 | Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona. |
| MX2015012300A MX368669B (es) | 2013-03-15 | 2014-03-17 | Procedimiento para la preparación de 4-amino-1-((1s,4r,5s)-2-fluor o-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-o na. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006783A MX385963B (es) | 2013-03-15 | 2014-03-17 | Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona. |
| MX2015012300A MX368669B (es) | 2013-03-15 | 2014-03-17 | Procedimiento para la preparación de 4-amino-1-((1s,4r,5s)-2-fluor o-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-o na. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9150520B2 (es) |
| EP (4) | EP4112604A1 (es) |
| JP (2) | JP6334676B2 (es) |
| KR (1) | KR20150130472A (es) |
| CN (3) | CN110483413B (es) |
| AU (3) | AU2014232502B8 (es) |
| BR (2) | BR122022026659B1 (es) |
| CA (3) | CA2904374C (es) |
| ES (3) | ES2913214T3 (es) |
| MX (3) | MX388587B (es) |
| WO (1) | WO2014145807A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014232502B8 (en) * | 2013-03-15 | 2018-01-18 | Rexahn Pharmaceuticals, Inc. | Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one |
| EP3307251B8 (en) | 2015-06-09 | 2021-12-01 | Ocuphire Pharma, Inc. | Fluorocyclopentenylcytosine uses and processes of preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968690A (en) * | 1986-05-27 | 1990-11-06 | United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services | 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it |
| US4820508A (en) * | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| CN1980898B (zh) * | 2004-04-01 | 2011-01-12 | 雷克斯安公司 | 核苷衍生物及其治疗用途 |
| AU2014232502B8 (en) * | 2013-03-15 | 2018-01-18 | Rexahn Pharmaceuticals, Inc. | Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one |
| EP3307251B8 (en) * | 2015-06-09 | 2021-12-01 | Ocuphire Pharma, Inc. | Fluorocyclopentenylcytosine uses and processes of preparation |
-
2014
- 2014-03-17 AU AU2014232502A patent/AU2014232502B8/en active Active
- 2014-03-17 CN CN201910733573.8A patent/CN110483413B/zh not_active Expired - Fee Related
- 2014-03-17 MX MX2019000207A patent/MX388587B/es unknown
- 2014-03-17 BR BR122022026659-2A patent/BR122022026659B1/pt active IP Right Grant
- 2014-03-17 CA CA2904374A patent/CA2904374C/en active Active
- 2014-03-17 MX MX2019006783A patent/MX385963B/es unknown
- 2014-03-17 CN CN201480015899.2A patent/CN105143191B/zh not_active Expired - Fee Related
- 2014-03-17 WO PCT/US2014/030635 patent/WO2014145807A1/en not_active Ceased
- 2014-03-17 CN CN201710609174.1A patent/CN107474034B/zh not_active Expired - Fee Related
- 2014-03-17 MX MX2015012300A patent/MX368669B/es active IP Right Grant
- 2014-03-17 EP EP22160928.2A patent/EP4112604A1/en active Pending
- 2014-03-17 EP EP14721670.9A patent/EP2970147B1/en active Active
- 2014-03-17 ES ES18170924T patent/ES2913214T3/es active Active
- 2014-03-17 EP EP18170924.7A patent/EP3378855B1/en active Active
- 2014-03-17 ES ES14721670.9T patent/ES2678085T3/es active Active
- 2014-03-17 BR BR112015023591-3A patent/BR112015023591B1/pt active IP Right Grant
- 2014-03-17 KR KR1020157028577A patent/KR20150130472A/ko not_active Ceased
- 2014-03-17 EP EP16206409.1A patent/EP3246320B1/en active Active
- 2014-03-17 CA CA3287371A patent/CA3287371A1/en active Pending
- 2014-03-17 ES ES16206409T patent/ES2740801T3/es active Active
- 2014-03-17 CA CA3160553A patent/CA3160553C/en active Active
- 2014-03-17 US US14/216,242 patent/US9150520B2/en active Active
- 2014-03-17 JP JP2016503433A patent/JP6334676B2/ja active Active
-
2015
- 2015-09-04 US US14/845,968 patent/US9533958B2/en active Active
-
2016
- 2016-12-15 US US15/379,553 patent/US9920016B2/en active Active
-
2017
- 2017-11-08 AU AU2017258856A patent/AU2017258856B2/en active Active
-
2018
- 2018-02-21 JP JP2018028988A patent/JP6503100B2/ja active Active
- 2018-10-25 AU AU2018253555A patent/AU2018253555B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502283A1 (en) | Anti-lag3 antibodies | |
| PH12018501159A1 (en) | Composition and methods for immunooncology | |
| PH12016501763B1 (en) | Multispecific antibodies | |
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
| WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
| AU2016263598A8 (en) | Methods and kits for treating depression | |
| EP3294450A4 (en) | PROCESS FOR PRODUCING MODIFIED CLAY, MODIFIED CLAY PRODUCED AND USE THEREOF | |
| MY205583A (en) | Acid-alpha glucosidase variants and uses thereof | |
| MX2024001617A (es) | Composiciones biofarmaceuticas. | |
| MY193650A (en) | Extracellular matrix compositions | |
| GB2568181A (en) | Wheat | |
| EA201600026A1 (ru) | Бактериальная гиалуронидаза и способ ее производства | |
| IN2013MU00848A (es) | ||
| IN2014MU00455A (es) | ||
| HUE040022T2 (hu) | Eljárás (S,S)-szekoizolaricirezinol diglükozid és (R,R)-szekoizolaricirezinol diglükozid elõállítására | |
| EP4480577A3 (en) | Structured elements and methods of use | |
| TW201613953A (en) | Process for the preparation of cyclic depsipeptides | |
| SG10201908248PA (en) | Processes for preparing fluoroketolides | |
| AU2018253555A1 (en) | Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one | |
| EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона | |
| MX383014B (es) | Formulaciones de antibióticos tópicas.. | |
| MX2015009565A (es) | Proceso para elaborar derivados de magnolol. | |
| IN2013CH05865A (es) | ||
| MX2016002186A (es) | Proceso para preparar dronedarona y sales de la misma. |